Polycystic ovary syndrome and reproductive behavior of today’s youth

A.A. Olina1, T.A. Meteleva2, N.M. Pirozhnikova2 1D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian Federation 2E.A. Vagner Perm State Medical University, Perm, Russian Federation Aim: to assess management strategy and efficacy of the treatment for polycystic ovary syndrome (PCOS) considering current international recommendations. Patients and Methods: retrospective analysis of 1,606 outpatient records of Perm students. Women with oligomenorrhea and amenorrhea (n=206) were included in the study group. Results: clinical signs of hyperandrogenism were revealed in 100% and multifollicular ovaries in 37.5% of study group women. Mean body mass index was 22.4±0.97 (normal body weight 63.1%, excess body weight 20.9%, obesity stage 1 14.6%, obesity stage 2 1.4%). Phenotype A was identified in 55 women (53.9%), phenotype B in 23 women (22.5%), phenotype C in 24 women (23.6%), and phenotype D was not identified.Anxiety assessment in women with PCOS using questionnaire demonstrated general health in 68.9%, minimal depression in 22.8%, mild depression in 7.3%, and moderate depression in 1.0%. All women with PCOS were prescribed with hormonal therapy, i .e., 100 women (98%) were prescribed with combined pills containing 20 μg of ethinyl estradiol and 3 mg of drospirenone (Dimia) taken daily for 28 days and 2 women (2%) were prescribed with progestogen-only pills (Lactinette-Richter) due to the verified migraine. After 6 months, 93% of women reported on reduced clinical signs of hyperandrogenism and recovery of menstrual function. Anxiety re-assessment has demonstrated general health in 73.3% and minimal depression in 26.7%. Conclusions: inadequate assessment of menstrual cycle without taking into account current characteristics of normal menstrual cycle accounts for overdiagnosis and, as a result, prescribing unnecessary treatment. PCOS rate in young fertile women with abnormal menstrual cycle was 49.5%. Clinical hyperandrogenism of various severity was identified in all women with PCOS. Ultra-low dose COCs containing drospirenone reduce the severity of clinical hyperandrogenism and recover menstrual function in 93% of women with PCOS and improves anxiety by 16.5%. Keywords: polyc ystic ovary syndrome, hyperandrogenism, acne, depression, COCs, drospirenone. For citation: Olina A.A., Meteleva T.A., Pirozhnikova N.M. Polycystic ovary syndrome and reproductive behavior of today’s youth. Russian Journal of Woman and Child Heal